Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ASPH | Q12797 | 2/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.37 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 2/20 | 0.34 |
| ▸ | LDHB | P07195 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312797 | 0.75 | ALDH1A1 (0.50) | KDM4ETYRALDH1A1TDP1GAA | |
| SCHEMBL9691086 | 0.75 | KDM4E (0.42) | KDM4EALDH1A1KMT2AHPGDALOX15 | |
| SCHEMBL1858272 | 0.74 | ALDH1A1 (0.49) | KDM4ETYRALDH1A1TDP1GAA | |
| SCHEMBL584940 | 0.73 | ALDH1A1 (0.55) | KDM4ETYRKDM4CALDH1A1TDP1 | |
| SCHEMBL5888693 | 0.73 | ALDH1A1 (0.49) | KDM4ETYRALDH1A1TDP1GAA | |
| SCHEMBL7712356 | 0.73 | ALDH1A1 (0.55) | KDM4EALDH1A1KMT2AHPGDALOX15 | |
| SCHEMBL9655344 | 0.71 | ALDH1A1 (0.39) | KDM4EALDH1A1KMT2AHPGDALOX15 | |
| SCHEMBL11109818 | 0.71 | TYR (0.44) | KDM4ETYRALDH1A1TDP1GAA | |
| SCHEMBL9690100 | 0.70 | XDH (0.37) | KDM4EALDH1A1KMT2AHPGDALOX15 | |
| SCHEMBL4471451 | 0.69 | DHFR (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | claimed |
| US-20080207673-A1 | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins | XILINAS MICHEL | 2008-08-28 | — | — | US | claimed |
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | UCL BUSINESS PLC (GB) | 2018-10-02 | — | — | US | disclosed |
| EP-3145914-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL Business PLC (GB) | 2017-03-29 | — | — | EP | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| WO-2015189560-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2006117660-A2 | METHOD FOR TREATING CANCER, CORONARY, INFLAMMATORY AND MACULAR DISEASE, COMBINING THE MODULATION OF ZINC- AND/OR COPPER DEPENDENT PROTEINS | CLIO PHARMACEUTICAL CORPORATION (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | CBR3, AGTR1, CBR1 | KDM4E 4288/4885ASPH 2621/4885KDM8 3073/4885 |
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | AGTR1, CBR3, CBR1 | KDM4E 4318/4885ASPH 2820/4885KDM8 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.